Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 06, 2022 4:01pm EDT
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress May 05, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 29, 2022 4:01pm EDT
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022 Apr 28, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 22, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 08, 2022 4:01pm EDT
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer Apr 05, 2022 4:01pm EDT
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm Apr 04, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Mar 04, 2022 4:01pm EST
